Key facts
- This page summarizes Stephen G. Dilly's Form 4 filing for Sierra Oncology, Inc..
- 5 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 01 Jul 2022, 16:35.
Stephen G. Dilly - 01 Jul 2022 Form 4 Insider Report for Sierra Oncology, Inc.
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- N/A
- Reported as of
- 01 Jul 2022
- Net transaction value
- -$275,000
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2022, 16:35:51 UTC
- Prior SEC filing
- 17 Jun 2022
- Next SEC filing
- 03 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary Christina Thomson, Attorney-In-Fact for Stephen George Dilly
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen G. Dilly filed Form 4 for Sierra Oncology, Inc. on 01 Jul 2022.
Change
- Previous filing in this sequence was filed on 17 Jun 2022.
- Current net transaction value: -$275,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SRRA
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $275,000
- Shares
- -5,000
- Change %
- -100%
- Price
- $55.00
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -520,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 520,000
- Exercise price
- $14.03
- Footnotes
- F1, F2
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -260,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 260,000
- Exercise price
- $12.15
- Footnotes
- F2, F3
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -92,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 92,000
- Exercise price
- $16.73
- Footnotes
- F2, F4
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -165,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 165,000
- Exercise price
- $31.54
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Stephen G. Dilly is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
The option vested as to 25% of the total shares on June 1, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on June 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F2
Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
Footnote F3
On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
Footnote F4
The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F5
The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.